​

Rapport Therapeutics (RAPP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RAPP Stock Forecast

Rapport Therapeutics (RAPP) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $65.56, with a high of $89.00 and a low of $50.00. This represents a 152.83% increase from the last price of $25.93.

$25 $38 $51 $64 $77 $90 High: $89 Avg: $65.56 Low: $50 Last Closed Price: $25.93

RAPP Stock Rating

Rapport Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

RAPP Price Target Upside V Benchmarks

TypeNameUpside
StockRapport Therapeutics152.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts71119
Avg Price Target$68.71$70.64$63.00
Last Closing Price$25.93$25.93$25.93
Upside/Downside164.98%172.43%142.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26112---13
Sep, 26112---13
Aug, 26112---13
Jul, 26111---12
Jun, 26110---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2026Ben BurnettWells Fargo$50.00$29.3770.24%92.83%
Oct 20, 2026Delma CaiatiGuggenheim$70.00$29.37138.34%169.96%
Oct 20, 2026Raymond James$86.00$29.19194.62%231.66%
Oct 20, 2026Kambiz YazdiBTIG$89.00$29.79198.76%243.23%
Oct 15, 2026Wolfe Research$50.00$28.3376.49%92.83%
Oct 15, 2026UBS$71.00$28.33150.62%173.81%
Oct 05, 2026Guggenheim$65.00$32.19101.93%150.67%
Sep 23, 2026UBS$80.00$41.4792.91%208.52%
Sep 16, 2026Kambiz YazdiBTIG$75.00$42.6875.73%189.24%
Aug 17, 2026Tiago FauthRaymond James$75.00$47.4258.16%189.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2026Wells FargoOverweightOverweighthold
Oct 20, 2026CitigroupOutperformOutperformhold
Oct 20, 2026GuggenheimBuyBuyhold
Oct 20, 2026Raymond JamesStrong BuyStrong Buyhold
Oct 20, 2026H.C. WainwrightBuyBuyhold
Oct 20, 2026Cowen & Co.BuyBuyhold
Oct 20, 2026BTIGBuyBuyhold
Oct 15, 2026Wolfe ResearchOutperforminitialise
Oct 15, 2026UBSStrong BuyBuyinitialise
Oct 05, 2026GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported$-0.38$-2.86
Avg Forecast$-3.65$-3.37
High Forecast$-3.29$-3.12
Low Forecast$-3.87$-3.70
Surprise %-89.59%-15.13%

Revenue Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-650M $-530M $-410M $-290M $-170M $-50M Dec 24 Dec 25
Dec 24Dec 25
Reported$-78.31M$-111.48M
Avg Forecast$-599.89M$-553.87M
High Forecast$-540.72M$-512.78M
Low Forecast$-636.05M$-608.11M
Surprise %-86.95%-79.87%

RAPP Forecast FAQ

Is Rapport Therapeutics stock a buy?

Rapport Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rapport Therapeutics is a favorable investment for most analysts.

What is Rapport Therapeutics's price target?

Rapport Therapeutics's price target, set by 7 Wall Street analysts, averages $65.56 over the next 12 months. The price target range spans from $50 at the low end to $89 at the high end, suggesting a potential 152.83% change from the previous closing price of $25.93.

How does Rapport Therapeutics stock forecast compare to its benchmarks?

Rapport Therapeutics's stock forecast shows a 152.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rapport Therapeutics over the past three months?

  • October 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.